Chronic Low Back Pain Market Research Report 2019 and Forecast to 2025


Report ID : RC-5456 Category : Healthcare
Published Date : January 2019 Pages : 154 Format : PDF
"Low back pain can be standardized into two categories, acute and chronic. Pain for less than three months can be classified as acute, while continued pain for more than three months is classified as chronic. When it comes to acute low back pain, most people get better with treatment at home. While, chronic low back pain (CLBP) is more complex and has been associated with neurochemical, structural, and functional cortical changes of several brain regions including the somatosensory cortex. Complex processes of peripheral and central sensitization may influence the evolution of acute to chronic pain. The Global Chronic Low Back Pain Market, which was esteemed at US$ 5.89 billion in 2016, is relied upon to achieve an estimation of US$ 9.19 billion by 2025, developing at a CAGR of 5.1% amid the forecast time frame of 2017-2025. 

The Global Chronic Low Back Pain Market is enhanced by factors such as:

• Sedentary lifestyle.
• Increasing nerve problems.
• Increasing use of emerging antidepressants.

Radiographic assessments for diagnosing the cause of the pain or discomfort in lower back involve the use of X-rays. An MRI scan is generally considered to be the single best imaging study of the spine to help plan treatment for back pain. The X-Ray segment, among other diagnosis segments, is anticipated as the leading segment, closely trailed by MRI. 
The analgesic medications segment is expected to lead the global market, followed by Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) during the forecast period. The multidisciplinary pain rehabilitation treatment incorporating analgesic medication withdrawal is associated with significant clinical improvements in physical and emotional functioning, regardless of lumbar spine surgical history.

The spinal fusion surgery segment is estimated to account for the leading share of the global market over the study period. Furthermore, it is expected that spinal fusion surgery will cure patients with chronic low back pain and this is partly responsible for an exponential increase in rates of spinal fusion around the world.

On the basis of end user segmentation, the hospitals held a dominant share in the previous years and are anticipated to attain growth at the fastest CAGR throughout the forecast period. Furthermore, the growing aging population, with an associated rise in the incidence of chronic low back pain, have also led to an increased demand for the global market.

Geographically, North America, Europe, Asia Pacific, Middle East and Africa and Latin America form the key regional segments. Out of these, North America accounted for the largest share of the Chronic Low Back Pain Market. North America is predicted to play a crucial role in the market revenue as well. It plays an important role in the global market, and any slight changes occurring on behalf of the U.S. is likely to have a considerable effect on the global market. 

Some of the leading players operational in the Global Chronic Low Back Pain Market include Stayble Therapeutics AB, Mesoblast INC, Axsome Therapeutics, INC, Norman Interventional Pain Management, Adynxx, INC.
"
"Table of Contents  

1. Introduction

1.1. Market Scope
1.2. Market Segmentation
1.3. Methodology
1.4. Assumptions

2. Chronic Low Back Pain Market Snapshot

2.1. Market Dynamic Snapshot
2.1.1. Comparative Analysis (Base year v/s. Forecast)
2.1.2. Geographic Outlook

3. Qualitative Analysis: Chronic Low Back Pain Market

3.1. Introduction
3.1.1. Product Definition
3.1.2. Industry Development
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Emerging Trends : Chronic Low Back Pain

4. Global Chronic Low Back Pain Market Analysis and Forecasts, 2017 - 2025

4.1. Overview
4.1.1. Global Chronic Low Back Pain Market Revenue (US$ Mn)
4.2. Global Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Diagnosis
4.2.1. Overview and Definition
4.2.2. X-Ray
4.2.3. Computerized Tomography (CT)
4.2.4. Myelograms
4.2.5. Discography
4.2.6. MRI
4.2.7. Electrodiagnostics
4.2.8. Bone Scans
4.2.9. Ultrasound Imaging
4.2.10. Others
4.3. Key Segment for Channeling Investments
4.3.1. By Diagnosis

5. Global Chronic Low Back Pain Market Analysis and Forecasts, 2017 - 2025

5.1. Overview
5.2. Global Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Treatment
5.2.1. Overview and Definition
5.2.2. Analgesic Medications
5.2.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
5.2.4. Anticonvulsants
5.2.5. Antidepressants
5.2.6. Counter-irritants
5.3. Key Segment for Channeling Investments
5.3.1. By Treatment

6. Global Chronic Low Back Pain Market Analysis and Forecasts, 2017 - 2025

6.1. Overview
6.2. Global Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Surgery
6.2.1. Overview and Definition
6.2.2. Vertebroplasty and kyphoplasty
6.2.3. Spinal laminectomy
6.2.4. Discectomy or microdiscectomy
6.2.5. Foraminotomy
6.2.6. Intradiscal electrothermal therapy (IDET)
6.2.7. Spinal fusion
6.2.8. Artificial disc replacement
6.2.9. Others
6.3. Key Segment for Channeling Investments
6.3.1. By Surgery

7. Global Chronic Low Back Pain Market Analysis and Forecasts, 2017 - 2025

7.1. Overview
7.2. Global Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By End User
7.2.1. Overview and Definition
7.2.2. Hospitals
7.2.3. Clinics
7.2.4. Ambulatory Surgical Centers
7.2.5. Others
7.3. Key Segment for Channeling Investments
7.3.1. By End User

8. North America Chronic Low Back Pain Market Analysis and Forecasts, 2017 - 2025

8.1. Overview
8.1.1. North America Chronic Low Back Pain Market Revenue (US$ Mn)
8.2. North America Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Diagnosis
8.2.1. X-Ray
8.2.2. Computerized Tomography (CT)
8.2.3. Myelograms
8.2.4. Discography
8.2.5. MRI
8.2.6. Electrodiagnostics
8.2.7. Bone Scans
8.2.8. Ultrasound Imaging
8.2.9. Others
8.3. North America Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Treatment
8.3.1. Analgesic Medications
8.3.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
8.3.3. Anticonvulsants
8.3.4. Antidepressants
8.3.5. Counter-irritants
8.4. North America Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Surgery
8.4.1. Vertebroplasty and kyphoplasty
8.4.2. Spinal laminectomy
8.4.3. Discectomy or microdiscectomy
8.4.4. Foraminotomy
8.4.5. Intradiscal electrothermal therapy (IDET)
8.4.6. Spinal fusion
8.4.7. Artificial disc replacement
8.4.8. Others
8.5. North America Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By End User
8.5.1. Hospitals
8.5.2. Clinics
8.5.3. Ambulatory Surgical Centers
8.5.4. Others
8.6. North America Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Country
8.6.1. U.S.
8.6.2. Rest of North America
8.7. Key Segment for channeling Investments
8.7.1. By Country
8.7.2. By Diagnosis
8.7.3. By Treatment
8.7.4. By Surgery
8.7.5. By End User

9. Europe Chronic Low Back Pain Market Analysis and Forecasts, 2017 - 2025

9.1. Overview
9.1.1. Europe Chronic Low Back Pain Market Revenue (US$ Mn)
9.2. Europe Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Diagnosis
9.2.1. X-Ray
9.2.2. Computerized Tomography (CT)
9.2.3. Myelograms
9.2.4. Discography
9.2.5. MRI
9.2.6. Electrodiagnostics
9.2.7. Bone Scans
9.2.8. Ultrasound Imaging
9.2.9. Others
9.3. Europe Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Treatment
9.3.1. Analgesic Medications
9.3.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
9.3.3. Anticonvulsants
9.3.4. Antidepressants
9.3.5. Counter-irritants
9.4. Europe Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Surgery
9.4.1. Vertebroplasty and kyphoplasty
9.4.2. Spinal laminectomy
9.4.3. Discectomy or microdiscectomy
9.4.4. Foraminotomy
9.4.5. Intradiscal electrothermal therapy (IDET)
9.4.6. Spinal fusion
9.4.7. Artificial disc replacement
9.4.8. Others
9.5. Europe Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By End User
9.5.1. Hospitals
9.5.2. Clinics
9.5.3. Ambulatory Surgical Centers
9.5.4. Others
9.6. Europe Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Country
9.6.1. France
9.6.2. The U.K.
9.6.3. Spain
9.6.4. Germany
9.6.5. Italy
9.6.6. Rest of Europe
9.7. Key Segment for channeling Investments
9.7.1. By Country
9.7.2. By Diagnosis
9.7.3. By Treatment
9.7.4. By Surgery
9.7.5. By End User

10. Asia Pacific Chronic Low Back Pain Market Analysis and Forecasts, 2017 - 2025

10.1. Overview
10.1.1. Asia Pacific Chronic Low Back Pain Market Revenue (US$ Mn)
10.2. Asia Pacific Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Diagnosis
10.2.1. X-Ray
10.2.2. Computerized Tomography (CT)
10.2.3. Myelograms
10.2.4. Discography
10.2.5. MRI
10.2.6. Electrodiagnostics
10.2.7. Bone Scans
10.2.8. Ultrasound Imaging
10.2.9. Others
10.3. Asia Pacific Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Treatment
10.3.1. Analgesic Medications
10.3.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
10.3.3. Anticonvulsants
10.3.4. Antidepressants
10.3.5. Counter-irritants
10.4. Asia Pacific Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Surgery
10.4.1. Vertebroplasty and kyphoplasty
10.4.2. Spinal laminectomy
10.4.3. Discectomy or microdiscectomy
10.4.4. Foraminotomy
10.4.5. Intradiscal electrothermal therapy (IDET)
10.4.6. Spinal fusion
10.4.7. Artificial disc replacement
10.4.8. Others
10.5. Asia Pacific Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By End User
10.5.1. Hospitals
10.5.2. Clinics
10.5.3. Ambulatory Surgical Centers
10.5.4. Others
10.6. Asia Pacific Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Country
10.6.1. China
10.6.2. Japan
10.6.3. India
10.6.4. Southeast Asia
10.6.5. Rest of Asia Pacific
10.7. Key Segment for channeling Investments
10.7.1. By Country
10.7.2. By Diagnosis
10.7.3. By Treatment
10.7.4. By Surgery
10.7.5. By End User

11. Middle East & Africa Chronic Low Back Pain Market Analysis and Forecasts, 2017 - 2025

11.1. Overview
11.1.1. Middle East & Africa Chronic Low Back Pain Market Revenue (US$ Mn)
11.2. Middle East & Africa Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Diagnosis
11.2.1. X-Ray
11.2.2. Computerized Tomography (CT)
11.2.3. Myelograms
11.2.4. Discography
11.2.5. MRI
11.2.6. Electrodiagnostics
11.2.7. Bone Scans
11.2.8. Ultrasound Imaging
11.2.9. Others
11.3. Middle East & Africa Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Treatment
11.3.1. Analgesic Medications
11.3.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
11.3.3. Anticonvulsants
11.3.4. Antidepressants
11.3.5. Counter-irritants
11.4. Middle East & Africa Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Surgery
11.4.1. Vertebroplasty and kyphoplasty
11.4.2. Spinal laminectomy
11.4.3. Discectomy or microdiscectomy
11.4.4. Foraminotomy
11.4.5. Intradiscal electrothermal therapy (IDET)
11.4.6. Spinal fusion
11.4.7. Artificial disc replacement
11.4.8. Others
11.5. Middle East & Africa Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By End User
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Ambulatory Surgical Centers
11.5.4. Others
11.6. Middle East & Africa Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Country
11.6.1. GCC Countries
11.6.2. Southern Africa
11.6.3. Rest of MEA
11.7. Key Segment for channeling Investments
11.7.1. By Country
11.7.2. By Diagnosis
11.7.3. By Treatment
11.7.4. By Surgery
11.7.5. By End User

12. Latin America Chronic Low Back Pain Market Analysis and Forecasts, 2017 - 2025

12.1. Overview
12.1.1. Latin America Chronic Low Back Pain Market Revenue (US$ Mn)
12.2. Latin America Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.2.1. X-Ray
12.2.2. Computerized Tomography (CT)
12.2.3. Myelograms
12.2.4. Discography
12.2.5. MRI
12.2.6. Electrodiagnostics
12.2.7. Bone Scans
12.2.8. Ultrasound Imaging
12.2.9. Others
12.3. Latin America Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Treatment
12.3.1. Analgesic Medications
12.3.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
12.3.3. Anticonvulsants
12.3.4. Antidepressants
12.3.5. Counter-irritants
12.4. Latin America Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Surgery
12.4.1. Vertebroplasty and kyphoplasty
12.4.2. Spinal laminectomy
12.4.3. Discectomy or microdiscectomy
12.4.4. Foraminotomy
12.4.5. Intradiscal electrothermal therapy (IDET)
12.4.6. Spinal fusion
12.4.7. Artificial disc replacement
12.4.8. Others
12.5. Latin America Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By End User
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Ambulatory Surgical Centers
12.5.4. Others
12.6. Latin America Chronic Low Back Pain Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. Brazil
12.6.2. Rest of Latin America
12.7. Key Segment for channeling Investments
12.7.1. By Country
12.7.2. By Diagnosis
12.7.3. By Treatment
12.7.4. By Surgery
12.7.5. By End User

13. Competitive Benchmarking

13.1. Market Positioning By Type Manufacturers
13.2. Global Presence and Growth Strategies
13.3. Market Share Analysis

14. Player Profiles

14.1. Stayble Therapeutics AB
14.1.1. Company Details
14.1.2. Company Overview
14.1.3. Key Developments
14.1.4. Financial Analysis
14.1.5. Key Strengths
14.1.6. Key Opportunities
14.1.7. Business Strategies
14.2. MESOBLAST INC.
14.3. Axsome Therapeutics, Inc.
14.4. Norman Interventional Pain Management
14.5. Adynxx, Inc.
14.6. Aestus Therapeutics, Inc.
14.7. Array BioPharma Inc.
14.8. Astellas Pharma Inc.
14.9. Egalet Corporation
14.10. Frontier Biotechnologies Co., Ltd
14.11. Gador S.A.
14.12. Grunenthal GmbH
14.13. Hisamitsu Pharmaceutical Co., Inc.
14.14. Immune Pharmaceuticals Inc.
14.15. Kineta, Inc.
14.16. MEDRx Co., Ltd.
14.17. Nektar Therapeutics
14.18. Orion Oyj
14.19. Pacira Pharmaceuticals, Inc.
14.20. Pfizer Inc.
14.21. Regeneron Pharmaceuticals, Inc.

15. Key Findings
 
"

Sidebar Menu